DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Tumor Ablation Market Size & Forecast By Technology, By Treatment By Application And Trend Analysis From 2015 To 2022" report to their offering.
Global tumor ablation market is expected to reach USD 1.5 billion by 2022. Rising prevalence of different forms of cancer and increasing technological advancements in the field of thermal ablation techniques are the most prominent drivers of the market.
Besides the use of thermal ablation, techniques such as laser ablation, irreversible electroporation, High Intensity Focused Ultrasonography (HIFU) are also clinically growing, concurrently propelling the tumor ablation industry.
Occurrence of lung, breast, and liver cancer is on the rise globally. According to the Center for Disease Control (CDC) and other organizations, currently, about 210,828 cases of lung cancer, 2.9 million cases of breast cancer, and over 2.7 million cases of prostate cancer are reported in the U.S. alone.
Lung cancer forms the most lucrative market and is anticipated to be the fastest growing segment over the forecast period. By 2022, it is expected to contribute about 15.0% of the revenue share owing to its rising prevalence rate across the globe.
According to market forecast for 2022, North America is expected to dominate the market and Asia Pacific is anticipated to witness the fastest growth. Augmenting growth in the cancer prevalence and rising healthcare expenditure in regions such as China, Korea, and India are factors responsible for this rapid growth.
- Medtronic Plc.
- Mermaid Medical
- Galil Medical Inc.
- EDAP TMS S.A.
- Boston Scientific Corporation
- SonaCare Medical
- Misonix, Inc.
- Neuwave Medical, Inc.
Key Topics Covered:
1. Methodology and Scope
2. Executive Summary
3. Tumor Ablation Devices Industry Outlook
4. Tumor Ablation Devices Technology Outlook
5. Tumor Ablation Devices Treatment Outlook
6. Tumor Ablation Devices Application Outlook
7. Tumor Ablation Devices Regional Outlook
8. Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/wb7nn4/tumor_ablation